Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
VanEck Pharmaceutical ETF (PPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/30/2025: PPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 5.73% | Avg. Invested days 55 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/30/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.56 | 52 Weeks Range 77.67 - 98.05 | Updated Date 06/30/2025 |
52 Weeks Range 77.67 - 98.05 | Updated Date 06/30/2025 |
Upturn AI SWOT
VanEck Pharmaceutical ETF
ETF Overview
Overview
The VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible the price and yield performance of the Indxx Global Pharmaceuticals Index, which is intended to track the overall performance of companies involved in the research, development, manufacturing, and marketing of pharmaceuticals.
Reputation and Reliability
VanEck has a strong reputation as an ETF provider with a long track record of managing sector-specific and global ETFs.
Management Expertise
VanEck has a dedicated team of investment professionals with experience in managing various types of ETFs, including sector-focused funds like PPH.
Investment Objective
Goal
To replicate the price and yield performance of the Indxx Global Pharmaceuticals Index.
Investment Approach and Strategy
Strategy: The ETF aims to track a specific index, the Indxx Global Pharmaceuticals Index.
Composition The ETF primarily holds stocks of pharmaceutical companies.
Market Position
Market Share: Data Unavailable
Total Net Assets (AUM): 322700000
Competitors
Key Competitors
- XBI
- IBB
- FXH
Competitive Landscape
The pharmaceutical ETF market is competitive, with several established players. PPH competes with broader biotechnology and healthcare ETFs, offering a more targeted exposure to pharmaceutical companies. Its advantage lies in its focused approach, while its disadvantage may be lower diversification compared to broader healthcare ETFs. Competition in the sector is based on factors like expense ratio, tracking error, and investment strategy.
Financial Performance
Historical Performance: Historical data needed for accurate performance analysis.
Benchmark Comparison: Performance comparison to the Indxx Global Pharmaceuticals Index is crucial for assessing tracking effectiveness.
Expense Ratio: 0.35
Liquidity
Average Trading Volume
Average trading volume data is needed to assess the liquidity of the ETF.
Bid-Ask Spread
The bid-ask spread data is needed to assess the cost of trading the ETF.
Market Dynamics
Market Environment Factors
Economic indicators, sector growth prospects (drug development, regulatory environment), and market conditions (interest rates, inflation) influence the performance of pharmaceutical stocks within the ETF. Specifically, the pharmaceutical industry is sensitive to regulatory changes, patent expirations, and clinical trial outcomes.
Growth Trajectory
The growth trajectory of the ETF depends on the performance of the pharmaceutical sector, which is influenced by factors like aging populations, advancements in drug development, and healthcare spending trends. Changes to strategy and holdings would be reflected in the fund's fact sheets and prospectuses.
Moat and Competitive Advantages
Competitive Edge
PPH offers focused exposure to global pharmaceutical companies, appealing to investors who believe in the sector's long-term growth. Its competitive edge lies in its targeted approach, allowing investors to capitalize on specific pharmaceutical industry trends. The ETF's strategy is to replicate the Indxx Global Pharmaceuticals Index which allows for targeted exposure to the global pharmaceutical sector. As an index tracking ETF, PPH offers transparent methodology and broad holdings within its targeted segment.
Risk Analysis
Volatility
Historical volatility is data unavailable.
Market Risk
The ETF is subject to market risk associated with the pharmaceutical sector, including regulatory risks, patent expirations, clinical trial failures, and competition from generic drugs. Changes in healthcare policy and economic downturns can also affect the performance of pharmaceutical companies.
Investor Profile
Ideal Investor Profile
The ideal investor is one seeking targeted exposure to the pharmaceutical sector and believes in the long-term growth potential of the industry. This investor is comfortable with the sector-specific risks associated with investing in pharmaceutical companies.
Market Risk
PPH is suitable for long-term investors and active traders looking for sector-specific exposure, but is less suitable for passive index followers seeking broad diversification.
Summary
VanEck Pharmaceutical ETF (PPH) provides targeted exposure to the global pharmaceutical sector by tracking the Indxx Global Pharmaceuticals Index. It is suitable for investors with a bullish outlook on the pharmaceutical industry and seeking to capitalize on the sector's growth potential. Key risks include regulatory challenges, patent expirations, and competition from generic drugs. Compared to broader healthcare ETFs, PPH offers a more focused approach but with potentially higher volatility. The investor profile best suited to this ETF has a higher risk tolerance and wants to invest in global pharmaceutical companies only.
Peer Comparison
Sources and Disclaimers
Data Sources:
- VanEck
- Indxx
- SEC Filings
- Various Financial News Outlets
Disclaimers:
The data and analysis provided are for informational purposes only and do not constitute financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VanEck Pharmaceutical ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.